Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ATP4A | P20648 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123146 | 0.85 | HSD17B10 (0.62) | MPLHSD17B10ALDH1A1KDM4EATP4A | |
| SCHEMBL38240 | 0.85 | HSD17B10 (0.62) | MPLHSD17B10ALDH1A1KDM4EATP4A | |
| Bromide SCHEMBL1915171 | 0.84 | HSD17B10 (0.61) | MPLHSD17B10ALDH1A1KDM4EATP4A | |
| SCHEMBL474191 | 0.84 | TYR (0.50) | MPLHSD17B10ALDH1A1CYP2D6KDM4E | |
| SCHEMBL1801817 | 0.83 | MPL (0.63) | MPLHSD17B10ALDH1A1CYP2D6KDM4E | |
| SCHEMBL3766189 | 0.82 | HTR2C (0.48) | MPLHSD17B10HTR2CNUDT1ALDH1A1 | |
| SCHEMBL1764977 | 0.81 | HTR2C (0.47) | HTR2CNUDT1ALDH1A1MAPK1SCN9A | |
| SCHEMBL28166445 | 0.79 | ALDH1A1 (0.52) | MPLHSD17B10ALDH1A1CYP2D6KDM4E | |
| SCHEMBL29654229 | 0.78 | CYP19A1 (0.63) | MPLHSD17B10ALDH1A1KDM4EATP4A | |
| SCHEMBL7432599 | 0.78 | HTR2C (0.60) | MPLHTR2CNUDT1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411395-B1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-07-12 | — | — | US | disclosed |
| EP-2411395-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109329-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178766-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | MPL 3150/4885HSD17B10 3242/4885HTR2C 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.